- Home
- ULCC vs SYRE Comparison
ULCC vs SYRE Comparison
Compare ULCC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- SYRE
- Stock Information
- Founded
- ULCC 1994
- SYRE 2013
- Country
- ULCC United States
- SYRE United States
- Employees
- ULCC N/A
- SYRE N/A
- Industry
- ULCC Air Freight/Delivery Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- SYRE Health Care
- Exchange
- ULCC Nasdaq
- SYRE Nasdaq
- Market Cap
- ULCC 1.1B
- SYRE 1.1B
- IPO Year
- ULCC 2021
- SYRE 2016
- Fundamental
- Price
- ULCC $3.60
- SYRE $23.46
- Analyst Decision
- ULCC Hold
- SYRE Strong Buy
- Analyst Count
- ULCC 9
- SYRE 5
- Target Price
- ULCC $5.63
- SYRE $55.75
- AVG Volume (30 Days)
- ULCC 3.8M
- SYRE 1.4M
- Earning Date
- ULCC 11-05-2025
- SYRE 11-06-2025
- Dividend Yield
- ULCC N/A
- SYRE N/A
- EPS Growth
- ULCC N/A
- SYRE N/A
- EPS
- ULCC N/A
- SYRE N/A
- Revenue
- ULCC $3,778,000,000.00
- SYRE N/A
- Revenue This Year
- ULCC $1.14
- SYRE N/A
- Revenue Next Year
- ULCC $13.33
- SYRE N/A
- P/E Ratio
- ULCC N/A
- SYRE N/A
- Revenue Growth
- ULCC 4.60
- SYRE N/A
- 52 Week Low
- ULCC $2.89
- SYRE $10.91
- 52 Week High
- ULCC $10.26
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- ULCC 37.74
- SYRE 63.91
- Support Level
- ULCC $4.11
- SYRE $23.52
- Resistance Level
- ULCC $3.88
- SYRE $25.06
- Average True Range (ATR)
- ULCC 0.25
- SYRE 1.24
- MACD
- ULCC -0.04
- SYRE 0.03
- Stochastic Oscillator
- ULCC 11.93
- SYRE 66.75
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.